EVALUATING RACIAL POPULATION (POP)-SPECIFIC RISK FOR CLINICALLY ACTIONABLE PHARMACOGENOMIC (PGX) GUIDANCE.

被引：0
|
作者：
Rizk, A. [1 ]
Danahey, K. [1 ]
Schierer, E. [1 ]
Perera, M. [2 ]
Meltzer, D. [1 ]
Ratain, M. [1 ]
O'Donnell, P. [1 ]
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Northwestern Univ, Chicago, IL 60611 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PGRN-025
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 11 条
  • [1] EVALUATING RACIAL POPULATION (POP)SPECIFIC RISK FOR CLINICALLY ACTIONABLE PHARMACOGENOMIC (PGX) GUIDANCE.
    Rizk, A.
    Danahey, K.
    Schierer, E.
    Perera, M.
    Meltzer, D.
    Ratain, M.
    O'Donnell, P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S58 - S58
  • [2] ANALYSIS OF ADULT IN-HOSPITAL MEDICATIONS FOR CLINICALLY ACTIONABLE PHARMACOGENOMIC (PGX) INFORMATION.
    Lee, Y.
    Danahey, K.
    Moscoe, G.
    Kreidich, L.
    Ratain, M. J.
    Meltzer, D. O.
    O'Don-Donnell, P. H.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S34 - S34
  • [3] ANALYSIS OF CLINICALLY ACTIONABLE PREEMPTIVE PHARMACOGENOMIC (PGx) INFORMATION TO IMPACT IN-HOSPITAL PRESCRIBING.
    Lee, Y.
    Danahey, K.
    Ratain, M. J.
    Meltzer, D. O.
    O'Donnell, P. H.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S107 - S107
  • [4] PREVALENCE OF CLINICALLY ACTIONABLE GENOTYPE RESULTS FOR ONCOLOGY DRUG-GENE INTERACTIONS (DGIS) AMONG PATIENTS (PTS) WITH PREEMPTIVE PHARMACOGENOMIC (PGX) TESTING.
    Reizine, N.
    Danahey, K.
    George, D.
    House, L.
    van Wijk, X.
    Yeo, K.
    Ratain, M.
    Vokes, E.
    O'Donnell, P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S68 - S68
  • [5] PREVALENCE OF CLINICALLY ACTIONABLE CYP2C19 AND CYP2D6 PHENOTYPES AND ANTIDEPRESSANTS WITH PHARMACOGENOMIC (PGX) INFORMATION PRESCRIBED AT THE UNIVERSITY OF CHICAGO.
    Nguyen, D.
    Danahey, K.
    Ratain, M.
    O'Donnell, P.
    Truong, T.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S38 - S38
  • [6] Pop-GUIDE: Population Modeling Guidance, Use, Interpretation, and Development for Ecological Risk Assessment
    Raimondo, Sandy
    Schmolke, Amelie
    Pollesch, Nathan
    Accolla, Chiara
    Galic, Nika
    Moore, Adrian
    Vaugeois, Maxime
    Rueda-Cediel, Pamela
    Kanarek, Andrew
    Awkerman, Jill
    Forbes, Valery
    [J]. INTEGRATED ENVIRONMENTAL ASSESSMENT AND MANAGEMENT, 2021, 17 (04) : 767 - 784
  • [7] Evaluating the Population Impact on Racial/Ethnic Disparities in HIV in Adulthood of Intervening on Specific Targets: A Conceptual and Methodological Framework
    Howe, Chanelle J.
    Dulin-Keita, Akilah
    Cole, Stephen R.
    Hogan, Joseph W.
    Lau, Bryan
    Moore, Richard D.
    Mathews, W. Christopher
    Crane, Heidi M.
    Drozd, Daniel R.
    Geng, Elvin
    Boswell, Stephen L.
    Napravnik, Sonia
    Eron, Joseph J., Jr.
    Mugavero, Michael J.
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2018, 187 (02) : 316 - 325
  • [8] Competing risk nomogram and risk classification system for evaluating overall and cancer-specific survival in neuroendocrine carcinoma of the cervix: a population-based retrospective study
    Liu, J.
    Lyu, Y.
    He, Y.
    Ge, J.
    Zou, W.
    Liu, S.
    Yang, H.
    Li, J.
    Jiang, K.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (06) : 1545 - 1557
  • [9] The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk
    Melia, J
    Dearnaley, D
    Moss, S
    Johns, L
    Coulson, P
    Moynihan, C
    Sweetman, J
    Parkinson, MC
    Eeles, R
    Watson, M
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (04) : 499 - 506
  • [10] The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk
    J Melia
    D Dearnaley
    S Moss
    L Johns
    P Coulson
    C Moynihan
    J Sweetman
    M C Parkinson
    R Eeles
    M Watson
    [J]. British Journal of Cancer, 2006, 94 : 499 - 506
12